stonks4u
Sign up free
GLSI logo

GLSI Greenwich LifeSciences, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$16.80
+0.42 (+2.56%)

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent …

Market Cap: $246.59Mgreenwichlifesciences.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 10Aug 10

Quote

Day Range
$15.92 – $17.42
52-Week Range
$7.78 – $34.10
Volume
$115.6K
Market Cap
$246.59M
50-Day Avg
$18.59
200-Day Avg
$20.51
Prev Close
$16.38
Open
$16.33

Valuation & Ratios

P/E Ratio
-14.69
EPS
$-1.43
P/B Ratio
805.09
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
1.06
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-5480.5%
Return on Assets
-313.3%
FCF Yield
-3.5%
EV/EBITDA
-14.37

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-19.36M$-1.43
2024$0.00$-17.41M$-1.21
2023$0.00$-8.89M$-0.69
2022$0.00$-7.83M$-0.61
2021$0.00$-4.57M$-0.35

Social Signal Score

70
5d
—
30d
70
1 mentions
—
60d
70
1 mentions
—
90d
70
1 mentions
—
news: 1

Earnings

Fri, Nov 13(in 3 months)

Consensus estimate $-0.34 per share

3of 7 quarters beat consensus

Typical surprise -4.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-0.27 vs $-0.33beat
  • Wed, Jun 3$-0.39 vs $-0.33miss
  • Tue, Mar 31$-0.32 vs $-0.32beat
  • Fri, Nov 14$-0.30 vs $-0.30beat
  • Thu, Aug 14$-0.30 vs $-0.24miss
  • Tue, May 20$-0.25 vs $-0.24miss

Estimates and results for GLSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

GLSIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5d ago·Positive

    Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Com

    View source ↗